Endologix Inc. (ELGX)

1.83
0.04 2.23
NASDAQ : Health Technology
Prev Close 1.79
Open 1.79
Day Low/High 1.79 / 1.88
52 Wk Low/High 1.64 / 6.72
Volume 635.50K
Avg Volume 680.00K
Exchange NASDAQ
Shares Outstanding 84.71M
Market Cap 149.93M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Endologix Appoints Jeffrey S. Brown As Chief Operations Officer

Endologix Appoints Jeffrey S. Brown As Chief Operations Officer

Endologix, Inc. (Nasdaq:ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jeffrey S.

Endologix Reports Second Quarter 2018 Financial Results

Endologix Reports Second Quarter 2018 Financial Results

Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2018.

Oversold Conditions For Endologix (ELGX)

Oversold Conditions For Endologix (ELGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ELGX Crosses Below Key Moving Average Level

ELGX Crosses Below Key Moving Average Level

In trading on Monday, shares of Endologix Inc. crossed below their 200 day moving average of $4.92, changing hands as low as $4.72 per share.

Endologix, Inc. To Announce Second Quarter 2018 Financial Results On August 9, 2018

Endologix, Inc. To Announce Second Quarter 2018 Financial Results On August 9, 2018

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2018 after the market close on Thursday, August 9, 2018.

Endologix Reports Positive 1-Year Results From The Ovation® LUCY Study

Endologix Reports Positive 1-Year Results From The Ovation® LUCY Study

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced 1-year results from the LUCY (Evaluation of Fema Les who are  Underrepresented  Candidates for Abdominal Aortic Aneur Ysm Repair) registry as...

Endologix Appoints Jeffry Fecho As Chief Quality Officer

Endologix Appoints Jeffry Fecho As Chief Quality Officer

Endologix, Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jeffry Fecho as the Company's Chief Quality Officer, effective as of June 25, 2018...

Endologix Appoints John Onopchenko As Chief Executive Officer

Endologix Appoints John Onopchenko As Chief Executive Officer

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John Onopchenko as the Company's Chief Executive Officer, effective immediately.

Endologix Reports First Quarter 2018 Financial Results

Endologix Reports First Quarter 2018 Financial Results

Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the first quarter ended March 31, 2018.

Endovascular Aneurysm Sealing (EVAS) With Nellix System Associated With Higher Survival Than Traditional Endovascular Aneurysm Repair (EVAR) In New Study

Endovascular Aneurysm Sealing (EVAS) With Nellix System Associated With Higher Survival Than Traditional Endovascular Aneurysm Repair (EVAR) In New Study

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the results of a study, which was presented by Marc Schermerhorn, M.

Endologix, Inc. To Announce First Quarter 2018 Financial Results On May 2, 2018

Endologix, Inc. To Announce First Quarter 2018 Financial Results On May 2, 2018

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2018 after the market...

Endologix Reports Positive Results From Global ENCORE Analysis With Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems

Endologix Reports Positive Results From Global ENCORE Analysis With Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the first results from ENCORE, a pooled, global analysis of several prospective clinical trials and...

Endologix, Inc. Announces Enrollment Of The First Patient In EVAS2 IDE Clinical Study Of The Nellix® EndoVascular Aneurysm Sealing System

Endologix, Inc. Announces Enrollment Of The First Patient In EVAS2 IDE Clinical Study Of The Nellix® EndoVascular Aneurysm Sealing System

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS2 IDE Confirmatory Clinical Study of the...

John McDermott Steps Down As Chief Executive Officer Of Endologix, Inc.

John McDermott Steps Down As Chief Executive Officer Of Endologix, Inc.

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott is stepping down as the Company's Chief Executive Officer.

Endologix Reports Fourth Quarter And Fiscal Year 2017 Financial Results

Endologix Reports Fourth Quarter And Fiscal Year 2017 Financial Results

Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.

Endologix, Inc. Completes Patient Enrollment In The ELEVATE IDE Clinical Study

Endologix, Inc. Completes Patient Enrollment In The ELEVATE IDE Clinical Study

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today the completion of enrollment in the E xpanding Patient Applicability with Po l ymer S e aling...

Endologix, Inc. To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Endologix, Inc. To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present...

Endologix Appoints Greg Morrow As Chief Marketing Officer And Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Appoints Greg Morrow As Chief Marketing Officer And Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Greg Morrow as the Company's Chief Marketing Officer, effective immediately.

Endologix, Inc. To Announce Fourth Quarter And Fiscal Year 2017 Financial Results On February 21, 2018

Endologix, Inc. To Announce Fourth Quarter And Fiscal Year 2017 Financial Results On February 21, 2018

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the fourth quarter and fiscal year 2017 after the market...

Endologix Becomes Oversold (ELGX)

Endologix Becomes Oversold (ELGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Endologix, Inc. To Present At The J.P. Morgan Healthcare Conference

Endologix, Inc. To Present At The J.P. Morgan Healthcare Conference

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present...

Endologix Reaches Analyst Target Price

Endologix Reaches Analyst Target Price

In recent trading, shares of Endologix Inc. have crossed above the average analyst 12-month target price of $5.33, changing hands for $5.39/share.

Endologix, Inc. To Present At The Piper Jaffray 29th Annual Healthcare Conference

Endologix, Inc. To Present At The Piper Jaffray 29th Annual Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, will present at the Piper Jaffray 29 th Annual Healthcare...

Endologix Reports Third Quarter 2017 Financial Results

Endologix Reports Third Quarter 2017 Financial Results

Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2017.

ELGX Crosses Above Average Analyst Target

ELGX Crosses Above Average Analyst Target

In recent trading, shares of Endologix Inc. have crossed above the average analyst 12-month target price of $5.70, changing hands for $5.92/share.

Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq:ELGX) ("Endologix"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to its newly appointed Chief Operating...

TheStreet Quant Rating: D (Sell)